CO5170457A1 - Profarmacos mutuos de amlodipino y atorvastatina - Google Patents
Profarmacos mutuos de amlodipino y atorvastatinaInfo
- Publication number
- CO5170457A1 CO5170457A1 CO00038315A CO00038315A CO5170457A1 CO 5170457 A1 CO5170457 A1 CO 5170457A1 CO 00038315 A CO00038315 A CO 00038315A CO 00038315 A CO00038315 A CO 00038315A CO 5170457 A1 CO5170457 A1 CO 5170457A1
- Authority
- CO
- Colombia
- Prior art keywords
- atorvastatin
- mutual
- prodrugs
- relates
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Esta invención se refiere a los profármacos mutuos de amlodipino y atorvastatina y a las composiciones farmacéuticas de los mismos. En especial a un compuesto de fórmula (I):<EMI FILE="00038315_1" ID="1" IMF=JPEG >o un compuesto de fórmula (II):<EMI FILE="00038315_2" ID="2" IMF=JPEG >en la que R1 y R2 se seleccionan independientemente entre H y alquilo (C1-C4), o una sal farmacéuticamente aceptable de los mismos. Esta invención también se refiere a los procedimientos para tratar la angina de pecho, la aterosclerosis y la hipertensión y la hiperlipidemia en un mamífero mediante el uso de estos profármacos y composiciones. Esta invención también se refiere a los procedimientos para tratar el riesgo cardíaco en un mamífero, incluyendo humanos, que presenta síntomas de riesgo cardíaco mediante la administración de estos profármacos y composiciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13660899P | 1999-05-27 | 1999-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5170457A1 true CO5170457A1 (es) | 2002-06-27 |
Family
ID=22473579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00038315A CO5170457A1 (es) | 1999-05-27 | 2000-05-24 | Profarmacos mutuos de amlodipino y atorvastatina |
Country Status (41)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| GB0027410D0 (en) * | 2000-11-09 | 2000-12-27 | Pfizer Ltd | Mutual prodrug of amlodipine and atorvastatin |
| US6737430B2 (en) | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
| WO2002100347A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| DE10140421A1 (de) * | 2001-08-17 | 2003-03-06 | Bayer Ag | Neue Kombination |
| US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| NZ554737A (en) | 2004-11-04 | 2011-04-29 | Xenoport Inc | Gabapentin prodrug sustained release oral dosage forms |
| WO2007016306A2 (en) * | 2005-08-01 | 2007-02-08 | Psivida Inc. | HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US8354116B2 (en) * | 2007-06-18 | 2013-01-15 | Biochemics, Inc. | Bifunctional synthetic molecules |
| US8371336B2 (en) | 2007-10-10 | 2013-02-12 | Eagle Industry Co., Ltd. | Accumulator |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5155120A (en) | 1991-01-14 | 1992-10-13 | Pfizer Inc | Method for treating congestive heart failure |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. |
-
2000
- 2000-03-20 AU AU33139/00A patent/AU3313900A/en not_active Abandoned
- 2000-03-20 WO PCT/IB2000/000313 patent/WO2000073298A1/en active IP Right Grant
- 2000-03-20 EP EP00911145A patent/EP1180102B9/en not_active Expired - Lifetime
- 2000-03-20 CN CN00808081A patent/CN1352640A/zh active Pending
- 2000-03-20 TR TR2001/03391T patent/TR200103391T2/xx unknown
- 2000-03-20 AT AT00911145T patent/ATE268764T1/de not_active IP Right Cessation
- 2000-03-20 CZ CZ20014229A patent/CZ20014229A3/cs unknown
- 2000-03-20 EA EA200101130A patent/EA200101130A1/ru unknown
- 2000-03-20 DK DK00911145T patent/DK1180102T3/da active
- 2000-03-20 MX MXPA01012125A patent/MXPA01012125A/es active IP Right Grant
- 2000-03-20 PL PL00353483A patent/PL353483A1/xx not_active Application Discontinuation
- 2000-03-20 IL IL14594700A patent/IL145947A0/xx unknown
- 2000-03-20 CA CA002375372A patent/CA2375372C/en not_active Expired - Fee Related
- 2000-03-20 EE EEP200100631A patent/EE200100631A/xx unknown
- 2000-03-20 HU HU0201433A patent/HUP0201433A2/hu unknown
- 2000-03-20 OA OA1200100312A patent/OA11950A/en unknown
- 2000-03-20 JP JP2000621364A patent/JP2003500487A/ja active Pending
- 2000-03-20 KR KR1020017015185A patent/KR20020012247A/ko not_active Application Discontinuation
- 2000-03-20 DE DE60011424T patent/DE60011424T2/de not_active Expired - Fee Related
- 2000-03-20 BR BR0011006-0A patent/BR0011006A/pt not_active IP Right Cessation
- 2000-03-20 ES ES00911145T patent/ES2220426T3/es not_active Expired - Lifetime
- 2000-03-20 AP APAP/P/2001/002345A patent/AP2001002345A0/en unknown
- 2000-03-20 PT PT00911145T patent/PT1180102E/pt unknown
- 2000-03-20 SK SK1679-2001A patent/SK16792001A3/sk unknown
- 2000-05-17 HN HN2000000075A patent/HN2000000075A/es unknown
- 2000-05-19 PA PA20008495701A patent/PA8495701A1/es unknown
- 2000-05-24 US US09/577,561 patent/US6486182B1/en not_active Expired - Fee Related
- 2000-05-24 CO CO00038315A patent/CO5170457A1/es not_active Application Discontinuation
- 2000-05-24 TN TNTNSN00113A patent/TNSN00113A1/fr unknown
- 2000-05-24 DZ DZ000092A patent/DZ3048A1/xx active
- 2000-05-24 MA MA25986A patent/MA26736A1/fr unknown
- 2000-05-25 GT GT200000078A patent/GT200000078A/es unknown
- 2000-05-25 PE PE2000000498A patent/PE20010169A1/es not_active Application Discontinuation
- 2000-05-25 SV SV2000000082A patent/SV2002000082A/es not_active Application Discontinuation
- 2000-05-26 AR ARP000102581A patent/AR022344A1/es not_active Application Discontinuation
-
2001
- 2001-10-30 IS IS6135A patent/IS6135A/is unknown
- 2001-11-19 HR HR20010856A patent/HRP20010856A2/hr not_active Application Discontinuation
- 2001-11-26 NO NO20015756A patent/NO20015756L/no not_active Application Discontinuation
- 2001-11-26 BG BG106149A patent/BG106149A/xx unknown
- 2001-11-26 ZA ZA200109691A patent/ZA200109691B/en unknown
-
2002
- 2002-10-30 HK HK02107872.6A patent/HK1046282A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5170457A1 (es) | Profarmacos mutuos de amlodipino y atorvastatina | |
| CO5271657A1 (es) | Derivados de azaindol | |
| CY1106996T1 (el) | Δισκιο με υψηλο φορτιο φαρμακου | |
| DK0712389T3 (da) | Terapeutisk forbindelse - fedtsyrekonjugater | |
| AR028994A1 (es) | Compuesto de sal mutua de amlodipino y atorvastatina y composiciones que la contienen | |
| DE69830504D1 (de) | Antithrombotische mitteln | |
| BG104076A (en) | Combined treatment including amplodipin and a statine compound | |
| AR028952A1 (es) | Antagonistas receptores de trombina | |
| CO5690131A1 (es) | Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento de transtornos del snc | |
| AR012269A1 (es) | COMPOSICIoN FARMACÉUTICA Y USO DE LA MISMA PARA LA FABRICACIoN DE MEDICAMENTOS | |
| ATE306261T1 (de) | Antithrombosemittel | |
| DE60114994D1 (de) | Blutplättchen-adp-rezeptor-inhibitoren | |
| ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
| NO20003018L (no) | Triazinangiogenese-inhibitorer | |
| SV1997000026A (es) | Composiciones farmaceuticas para el tratamiento de la rinitis | |
| CO5261493A1 (es) | Procedimiento y compuestos para la inhibicion de la mrp1 | |
| MX9306309A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| EA200100906A1 (ru) | Композиция контролируемого высвобождения для лечения copd хронического обструктивного заболевания легких | |
| UY27034A1 (es) | Derivados de pirimidina | |
| CO5150166A1 (es) | (s)-10, 11-dihidro-3[2-(5,6,7,8-tetrahidro-1,8-naftiridin -2-il)-etoxi]-5h-dibenzo [a,d] cicloheptano-10-acido acetico | |
| GT199700116A (es) | Composiciones farmaceuticas | |
| PA8444901A1 (es) | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios | |
| ECSP003493A (es) | Profarmacos mutuos de amlodipino y atorvastatina | |
| UY26164A1 (es) | Profarmácos mutuos de amlodipino y atorvastatina | |
| BR0005122A (pt) | Método para a preparação de inibidor de permutador de sódio-hidrogênio do tipo 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |